Elanco Animal Health (ELAN)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NYSE
Market Cap: $13.39B
Last updated: Nov 17, 2026 at 11:05 AM ET
Elanco Animal Health (ELAN) Financials: Revenue, Profit and Cash Flow
Elanco Animal Health reported revenue of $4.71B for the fiscal year ended Dec 31, 2025, up 6.2% from the year before. That year, net income was -$232.00M with a net margin of -4.9%, operating cash flow was $560.00M and free cash flow was $284.00M. The quarter ended Sep 30, 2026 had revenue of $1.26B and net income of $18.00M.
Revenue and Margins
The operating margin was -0.1% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $2.91B, a compound annual rate of 5.5%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $4.71B | +6.2% | 55.0% | -0.1% | -4.9% |
| Dec 2024 | $4.44B | +0.5% | 54.9% | 1.9% | 7.6% |
| Dec 2023 | $4.42B | +0.1% | 56.3% | -20.8% | -27.9% |
| Dec 2022 | $4.41B | -7.4% | 56.6% | 3.8% | -1.8% |
| Dec 2021 | $4.76B | +45.6% | 55.2% | -7.0% | -10.1% |
| Dec 2020 | $3.27B | +6.5% | 49.0% | -21.6% | -17.5% |
| Dec 2019 | $3.07B | +0.1% | 52.1% | 6.0% | 2.2% |
| Dec 2018 | $3.07B | +6.2% | 48.7% | 4.7% | 2.8% |
| Dec 2017 | $2.89B | -0.8% | 48.3% | -8.1% | -10.8% |
| Dec 2016 | $2.91B | N/A | 51.6% | -0.9% | -1.6% |
Income Statement
In the fiscal year ended Dec 2025, the company posted a net loss after a profit the year before. In the quarter ended Sep 2026, net income turned positive after a loss in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.71B | $4.44B | $4.42B | $4.41B | $4.76B | $3.27B | $3.07B | $3.07B | $2.89B | $2.91B |
| Cost of revenue | $2.12B | $2.00B | $1.93B | $1.91B | $2.13B | $1.67B | $1.47B | $1.57B | $1.49B | $1.41B |
| Gross profit | $2.59B | $2.44B | $2.49B | $2.50B | $2.63B | $1.60B | $1.60B | $1.49B | $1.40B | $1.50B |
| Research and development | $368.00M | $344.00M | $327.00M | $321.00M | $369.00M | $329.00M | $270.00M | $246.60M | $251.70M | $265.80M |
| Operating income | -$4.00M | $83.00M | -$918.00M | $169.00M | -$335.00M | -$705.00M | $185.00M | $143.70M | -$232.70M | -$25.20M |
| Net income | -$232.00M | $338.00M | -$1.23B | -$78.00M | -$483.00M | -$574.00M | $68.00M | $86.50M | -$310.70M | -$47.90M |
| EBITDA | $676.00M | $1.39B | -$224.00M | $851.00M | $445.00M | $80.00M | $472.00M | $439.70M | $85.80M | $232.00M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.26B | $1.37B | $1.37B | $1.14B | $1.14B | $1.24B | $1.19B | $1.02B | $1.03B | $1.18B | $1.21B | $1.03B |
| Gross profit | $720.00M | $798.00M | $785.00M | $589.00M | $607.00M | $713.00M | $684.00M | $519.00M | $538.00M | $689.00M | $690.00M | $519.00M |
| Operating income | $83.00M | $115.00M | $144.00M | -$202.00M | $2.00M | $84.00M | $112.00M | -$14.00M | -$23.00M | $33.00M | $87.00M | -$78.00M |
| Net income | $18.00M | $54.00M | $57.00M | -$276.00M | -$34.00M | $11.00M | $67.00M | -$8.00M | $364.00M | -$50.00M | $32.00M | -$141.00M |
Balance Sheet
As of Dec 2025, total debt of $4.02B exceeded cash and equivalents by $3.47B.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $13.36B | $12.61B | $14.36B | $15.49B | $16.48B | $17.69B | $8.99B | $8.96B | $8.94B | $8.10B |
| Current assets | $3.46B | $3.21B | $3.41B | $3.28B | $3.27B | $3.42B | $2.37B | $2.50B | $2.12B | $1.95B |
| Cash and equivalents | $545.00M | $468.00M | $352.00M | $345.00M | $638.00M | $495.00M | $334.00M | $474.80M | $323.40M | $258.80M |
| Total liabilities | $6.81B | $6.52B | $8.14B | $8.20B | $8.97B | $9.22B | $3.44B | $3.76B | $1.16B | $1.07B |
| Short-term debt | $74.00M | $44.00M | $38.00M | $388.00M | $294.00M | $555.00M | $24.50M | $29.00M | $0 | N/A |
| Long-term debt | $3.94B | $4.28B | $5.74B | $5.45B | $6.03B | $5.57B | $2.33B | $2.44B | $0 | N/A |
| Shareholder equity | $6.55B | $6.10B | $6.22B | $7.29B | $7.51B | $8.48B | $5.55B | $5.20B | $7.78B | $7.03B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $13.34B | $13.56B | $13.22B | $13.36B | $13.55B | $13.74B | $12.94B | $12.61B | $13.28B | $13.76B | $14.02B | $14.36B |
| Total liabilities | $6.71B | $6.97B | $6.72B | $6.81B | $6.80B | $6.97B | $6.59B | $6.52B | $6.76B | $7.82B | $7.96B | $8.14B |
| Cash and equivalents | $465.00M | $530.00M | $428.00M | $545.00M | $505.00M | $539.00M | $487.00M | $468.00M | $490.00M | $416.00M | $345.00M | $352.00M |
| Shareholder equity | $6.63B | $6.59B | $6.50B | $6.55B | $6.75B | $6.78B | $6.35B | $6.10B | $6.52B | $5.94B | $6.06B | $6.22B |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 50.7% of operating cash flow.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $560.00M | $541.00M | $271.00M | $452.00M | $483.00M | -$41.00M | $224.00M | $487.30M | $173.80M | $155.90M |
| Capital expenditures | $276.00M | $147.00M | $140.00M | $171.00M | $159.00M | $135.00M | $140.00M | $134.50M | $98.60M | $110.30M |
| Free cash flow | $284.00M | $394.00M | $131.00M | $281.00M | $324.00M | -$176.00M | $84.00M | $352.80M | $75.20M | $45.60M |
| Investing cash flow | -$279.00M | $1.16B | -$169.00M | -$179.00M | -$530.00M | -$4.78B | -$235.00M | -$127.00M | -$964.60M | -$182.10M |
| Financing cash flow | -$275.00M | -$1.49B | -$83.00M | -$549.00M | $210.00M | $4.95B | -$305.00M | -$35.20M | $847.50M | -$149.60M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $216.00M | $277.00M | $13.00M | $108.00M | $219.00M | $237.00M | -$4.00M | $177.00M | $162.00M | $200.00M | $2.00M | $157.00M |
| Capital expenditures | $60.00M | $33.00M | $51.00M | $62.00M | $92.00M | $57.00M | $65.00M | $47.00M | $42.00M | $34.00M | $24.00M | $41.00M |
| Free cash flow | $156.00M | $244.00M | -$38.00M | $46.00M | $127.00M | $180.00M | -$69.00M | $130.00M | $120.00M | $166.00M | -$22.00M | $116.00M |
Frequently Asked Questions About ELAN
What is Elanco Animal Health's annual revenue?
Elanco Animal Health reported revenue of $4.71B for the fiscal year ended Dec 31, 2025.
How fast is Elanco Animal Health's revenue growing?
Revenue was up 6.2% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 2.2%.
Is Elanco Animal Health profitable?
No. Elanco Animal Health reported net income of -$232.00M for the fiscal year ended Dec 31, 2025, with a net margin of -4.9%.
How much free cash flow does ELAN generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $560.00M minus capital expenditures of $276.00M produced free cash flow of $284.00M.
How much debt does Elanco Animal Health have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $3.94B, short-term debt of $74.00M and cash and equivalents of $545.00M.
ELAN pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors